BRAF/MEK inhibitors

What it is

BRAF and MEK inhibitors are targeted drugs that block the overactive MAPK growth pathway in gliomas with BRAF changes (such as the BRAF V600E mutation). They are particularly used in certain pediatric low-grade gliomas and other BRAF-altered tumors, offering an effective option when surgery is not sufficient.

Understanding BRAF/MEK inhibitors

Many pediatric low-grade gliomas (and some other gliomas) are driven by activation of the MAPK pathway, often through BRAF changes. BRAF inhibitors block the mutant BRAF protein directly (for BRAF V600E-mutant tumors), and MEK inhibitors block a downstream step in the pathway (useful for various MAPK-activating changes, including BRAF fusions); the two are sometimes combined. These targeted drugs can shrink or control tumors driven by these changes, which is especially valuable for tumors that cannot be fully removed by surgery or that recur — for example, optic pathway gliomas and other pediatric low-grade gliomas. Identifying the relevant BRAF or pathway alteration through molecular testing determines whether these drugs are an option, underscoring the value of such testing. BRAF/MEK inhibitors exemplify targeting the driver pathway of pediatric gliomas. They have specific side effects that are monitored. Understanding BRAF/MEK inhibitors in gliomas clarifies targeted drugs for BRAF-pathway-driven tumors.

Why it matters

Understanding BRAF/MEK inhibitors helps families see targeted drugs that block the growth pathway driving many pediatric low-grade gliomas — an effective option when surgery is not sufficient, guided by molecular testing.